Conatus Pharma Q1 Loss Widens

(RTTNews) - Conatus Pharmaceuticals (CNAT) posted first-quarter net loss applicable to common stockholders of $5.2 million, wider than $2.3 million in the comparable quarter last year. Loss per share for the latest first quarter was $0.34, narrower than $2.17 last year.

On average, four analysts polled by Thomson Reuters expected the company to report a loss of $0.33 per share.

Research and development expenses were $3.65 million, compared with $968 thousand last year, while general and administrative expenses were $1.60 million, up from $0.7 million in the year-ago period.